Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Rating Cut to “Strong Sell” at Zacks Research

Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from a hold rating to a strong sell rating in a report issued on Thursday morning,Zacks reports.

A number of other analysts also recently commented on FMS. Citigroup reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Berenberg Bank set a $24.00 price target on Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, September 29th. Sanford C. Bernstein lifted their price target on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Finally, Truist Financial decreased their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.00 to $24.00 and set a “hold” rating on the stock in a research report on Monday, October 12th. Seven analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $23.42.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of NYSE:FMS traded up $0.03 during trading on Thursday, hitting $22.16. 620,732 shares of the stock were exchanged, compared to its average volume of 1,011,595. The company has a market cap of $11.90 billion, a PE ratio of 11.48, a P/E/G ratio of 4.09 and a beta of 0.74. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a fifty day moving average price of $22.65 and a two-hundred day moving average price of $22.88. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $20.02 and a 12-month high of $27.43.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.04. The firm had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. On average, analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.25 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of FMS. Farther Finance Advisors LLC grew its holdings in Fresenius Medical Care AG & Co. KGaA by 39.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,915 shares of the company’s stock valued at $43,000 after buying an additional 538 shares during the last quarter. Advisors Preferred LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 6.1% during the first quarter. Advisors Preferred LLC now owns 10,226 shares of the company’s stock worth $231,000 after buying an additional 589 shares in the last quarter. Allworth Financial LP increased its position in Fresenius Medical Care AG & Co. KGaA by 31.5% during the second quarter. Allworth Financial LP now owns 3,552 shares of the company’s stock worth $80,000 after buying an additional 850 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 27.9% in the first quarter. Parallel Advisors LLC now owns 4,632 shares of the company’s stock worth $104,000 after acquiring an additional 1,011 shares during the last quarter. Finally, Mather Group LLC. raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 838.0% in the third quarter. Mather Group LLC. now owns 1,407 shares of the company’s stock worth $31,000 after acquiring an additional 1,257 shares during the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney disease and kidney failure. The company provides dialysis care through a global network of outpatient clinics and supports patients with related medical services, including vascular access care, laboratory services and care coordination.

In addition to operating dialysis facilities, Fresenius Medical Care develops and manufactures products used in dialysis treatment.